Diagnostics

HCAP Partners Launches Integrated Diagnostic Services to Expand Access to Mobile Imaging and Diagnostics

HCAP Partners, a California-based private equity firm and nationally recognized impact investor, announces the launch of Integrated Diagnostic Services, a mobile diagnostics company focused on expanding access to mobile X-ray, ultrasound, electrocardiogram (EKG), echocardiogram services, and laboratory services for residents of skilled nursing facilities, long term care facilities, and home health providers. Integrated Diagnostic Services […]

HCAP Partners Launches Integrated Diagnostic Services to Expand Access to Mobile Imaging and Diagnostics Read More »

Labcorp Announces Acquisition of Select Assets of BioReference Health’s Innovative Oncology and Related Clinical Testing Services Businesses

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announce that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference

Labcorp Announces Acquisition of Select Assets of BioReference Health’s Innovative Oncology and Related Clinical Testing Services Businesses Read More »

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, has announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline Read More »

23andMe Special Committee Again Rejects CEO Wojcicki’s Take-Private Offer

23andMe’s special committee of independent directors on Monday rejected CEO Anne Wojcicki’s proposal to take the distressed genetic testing company private. Wojcicki submitted a proposal to the committee on Sunday, offering to acquire all of the company’s outstanding shares for 41 cents each, according to a filing with the U.S. Securities and Exchange Commission. Wojcicki

23andMe Special Committee Again Rejects CEO Wojcicki’s Take-Private Offer Read More »

NPPN and PhlebX Announce Merger, Creating Dash Health, a National Mobile Diagnostic Platform

The National Phlebotomy Provider Network (NPPN) and PhlebX have announced plans to merge and form Dash Health, the most advanced and comprehensive mobile diagnostic services platform in the United States. This merger combines decades of expertise in mobile specimen collection with cutting-edge technology to create a seamless, data-driven healthcare experience for patients, providers, and payers

NPPN and PhlebX Announce Merger, Creating Dash Health, a National Mobile Diagnostic Platform Read More »

Scroll to Top